Chapter

Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer

Samir A. Farghaly

in Ovarian Cancer Immunotherapy

Published on behalf of Oxford University Press

Published in print August 2018 | ISBN: 9780190248208
Published online September 2018 | e-ISBN: 9780190248239 | DOI: https://dx.doi.org/10.1093/med/9780190248208.003.0005
Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer

More Like This

Show all results sharing these subjects:

  • Radiation Oncology
  • Obstetrics and Gynaecology

GO

Show Summary Details

Preview

The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.

Chapter.  5293 words.  Illustrated.

Subjects: Radiation Oncology ; Obstetrics and Gynaecology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.